Cite
HARVARD Citation
Schmitt, W. et al. (2021). NT‐proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure. Clinical pharmacology & therapeutics. 110 (2), pp. 498-507. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Schmitt, W. et al. (2021). NT‐proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure. Clinical pharmacology & therapeutics. 110 (2), pp. 498-507. [Online].